Drug Trial Radar · NCT07482813
An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Sep 19, 2027
Study completion Oct 19, 2027
Sponsor
- Lead sponsor
- Paradigm TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 28 days, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to characterize the continued safety of SD-101 cream containing 6% allantoin in the treatment of the skin in patients with Simplex, Recessive Dystrophic, or JEB-nH EB.
Conditions
- Epidermolysis Bullosa (EB)
Interventions
SD-101 Dermal Cream (6%)Drug
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measuring safety of SD-101-6.0Time frame: 1 Year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.